Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'.
作者信息
Neelapu Sattva S, Tummala Sudhakar, Kebriaei Partow, Wierda William, Locke Frederick L, Lin Yi, Jain Nitin, Daver Naval, Gulbis Alison M, Adkins Sherry, Rezvani Katayoun, Hwu Patrick, Shpall Elizabeth J
机构信息
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center.
Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center.
出版信息
Nat Rev Clin Oncol. 2018 Apr;15(4):218. doi: 10.1038/nrclinonc.2018.20. Epub 2018 Feb 13.
Abstract
摘要
相似文献
1
Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'.嵌合抗原受体T细胞疗法后的毒性管理：“一刀切”并不适用于所有“急性淋巴细胞白血病（ALL）”患者 。 （注：这里ALL结合语境推测为急性淋巴细胞白血病，若原文有特殊含义需根据实际调整）
Nat Rev Clin Oncol. 2018 Apr;15(4):218. doi: 10.1038/nrclinonc.2018.20. Epub 2018 Feb 13.
2
Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'.嵌合抗原受体T细胞疗法后的毒性管理：“一刀切”并不适用于所有“急性淋巴细胞白血病（ALL）”患者 。 （注：这里根据语境补充了ALL是急性淋巴细胞白血病的意思，因为仅从英文看ALL指代不明，添加此注释是为了让译文更完整准确理解，但按照要求不能添加其他解释说明，所以译文按原文直接翻译并补充说明放在括号里供理解。）
Nat Rev Clin Oncol. 2018 Apr;15(4):218. doi: 10.1038/nrclinonc.2018.19. Epub 2018 Feb 13.
3
Enhanced chimeric antigen receptor T-cell therapy: A novel approach for head and neck cancers.增强型嵌合抗原受体T细胞疗法：一种治疗头颈癌的新方法。
Oral Dis. 2019 Mar;25(2):355-356. doi: 10.1111/odi.12884. Epub 2018 May 29.
4
[Chimeric antigen receptor T cell (CAR-T) therapy for refractory/relapsed hematological malignancy].[嵌合抗原受体T细胞（CAR-T）疗法治疗难治性/复发性血液系统恶性肿瘤]
Rinsho Ketsueki. 2018;59(10):1948-1954. doi: 10.11406/rinketsu.59.1948.
5
Insights into Chimeric Antigen Receptor Therapy for Chronic Lymphoblastic Leukemia.嵌合抗原受体疗法治疗慢性淋巴细胞白血病的研究进展。
Trends Mol Med. 2018 Sep;24(9):729-731. doi: 10.1016/j.molmed.2018.06.007. Epub 2018 Jul 4.
6
Chimeric Antigen Receptor T-cell Immunotherapy and Need for Prophylaxis for Invasive Mold Infections.嵌合抗原受体T细胞免疫疗法与侵袭性霉菌感染的预防需求
Clin Infect Dis. 2020 Oct 23;71(7):1802-1803. doi: 10.1093/cid/ciaa031.
7
Chimeric Antigen Receptor T-Cell Neurotoxicity Neuroimaging: More Than Meets the Eye.嵌合抗原受体T细胞神经毒性的神经影像学：所见不止于此。
AJNR Am J Neuroradiol. 2019 Oct;40(10):E50-E51. doi: 10.3174/ajnr.A6184. Epub 2019 Sep 5.
8
Chimeric Antigen Receptor T-cell Therapy in Prostate Cancer: Reality or Folly?嵌合抗原受体T细胞疗法治疗前列腺癌：现实还是 folly？ （注：folly 在这里直接保留英文，因为不清楚其在原文语境中的准确含义，可能是特定术语或有特殊指代，按要求不添加解释说明）
Eur Urol. 2020 Mar;77(3):309-310. doi: 10.1016/j.eururo.2019.12.002. Epub 2019 Dec 19.
9
Chimeric antigen receptor T-cell therapy for acute lymphocytic leukaemia: where are we in 2020?嵌合抗原受体T细胞疗法治疗急性淋巴细胞白血病：2020年我们处于什么阶段？
Lancet Haematol. 2020 Nov;7(11):e778-e779. doi: 10.1016/S2352-3026(20)30284-2.
10
Surviving the storm: critical care outcomes of chimeric antigen receptor T-cell therapy.挺过风暴：嵌合抗原受体T细胞疗法的重症监护结果
Lancet Haematol. 2021 May;8(5):e311-e312. doi: 10.1016/S2352-3026(21)00097-1.
引用本文的文献
1
[CAR T-cell therapy of mature B-cell neoplasms-Current use and practical considerations].[成熟B细胞肿瘤的嵌合抗原受体T细胞疗法——当前应用及实际考量]
Inn Med (Heidelb). 2025 Jul 11. doi: 10.1007/s00108-025-01953-x.
2
Barriers and solutions for CAR-T therapy in solid tumors.实体瘤中CAR-T疗法的障碍与解决方案
Cancer Gene Ther. 2025 Jun 27. doi: 10.1038/s41417-025-00931-7.
3
Influence of CAR T-cell therapy associated complications.嵌合抗原受体T细胞（CAR T）疗法相关并发症的影响。
Front Oncol. 2025 Feb 20;15:1494986. doi: 10.3389/fonc.2025.1494986. eCollection 2025.
4
Soluble factors released by peripheral blood-derived CAR-NK cells cause bystander myeloid cell activation.外周血来源的CAR-NK细胞释放的可溶性因子导致旁观者髓系细胞活化。
Front Immunol. 2024 Dec 24;15:1519415. doi: 10.3389/fimmu.2024.1519415. eCollection 2024.
5
From ex vivo to in vivo chimeric antigen T cells manufacturing: new horizons for CAR T-cell based therapy.从体外到体内嵌合抗原T细胞制造：基于CAR-T细胞疗法的新视野
J Transl Med. 2025 Jan 4;23(1):10. doi: 10.1186/s12967-024-06052-3.
6
Cancer Therapy-Induced Encephalitis.癌症治疗诱发的脑炎
Cancers (Basel). 2024 Oct 23;16(21):3571. doi: 10.3390/cancers16213571.
7
Revolutionizing cancer treatment: an in-depth exploration of CAR-T cell therapies.颠覆癌症治疗：CAR-T 细胞疗法的深入探索。
Med Oncol. 2024 Oct 14;41(11):275. doi: 10.1007/s12032-024-02491-6.
8
IL-6 Blockade in Cytokine Storm Syndromes.白细胞介素-6 阻断在细胞因子风暴综合征中的应用。
Adv Exp Med Biol. 2024;1448:565-572. doi: 10.1007/978-3-031-59815-9_37.
9
The Unprecedented Success of Chimeric Antigen Receptor T-Cell Therapy in the Treatment of Hematological Malignancies.嵌合抗原受体T细胞疗法在血液系统恶性肿瘤治疗中取得的空前成功。
Cureus. 2024 May 9;16(5):e59951. doi: 10.7759/cureus.59951. eCollection 2024 May.
10
Protocol for a mixed-methods study to develop and feasibility test a digital system for the capture of patient-reported outcomes (PROs) in patients receiving chimeric antigen receptor T-cell (CAR-T) therapies (the PRO-CAR-T study).嵌合抗原受体 T 细胞（CAR-T）疗法治疗患者中患者报告结局（PROs）采集数字系统的开发和可行性测试的混合方法研究方案（PRO-CAR-T 研究）。
BMJ Open. 2024 Mar 29;14(3):e085392. doi: 10.1136/bmjopen-2024-085392.
本文引用的文献
1
Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'.嵌合抗原受体T细胞疗法后的毒性管理：“一刀切”并不适用于所有“急性淋巴细胞白血病（ALL）”患者 。 （注：这里根据语境补充了ALL是急性淋巴细胞白血病的意思，因为仅从英文看ALL指代不明，添加此注释是为了让译文更完整准确理解，但按照要求不能添加其他解释说明，所以译文按原文直接翻译并补充说明放在括号里供理解。）
Nat Rev Clin Oncol. 2018 Apr;15(4):218. doi: 10.1038/nrclinonc.2018.19. Epub 2018 Feb 13.
2
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.阿基仑赛注射液嵌合抗原受体T细胞疗法治疗难治性大B细胞淋巴瘤
N Engl J Med. 2017 Dec 28;377(26):2531-2544. doi: 10.1056/NEJMoa1707447. Epub 2017 Dec 10.
3
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.难治性B细胞淋巴瘤中的嵌合抗原受体T细胞
N Engl J Med. 2017 Dec 28;377(26):2545-2554. doi: 10.1056/NEJMoa1708566. Epub 2017 Dec 10.
4
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.嵌合抗原受体 T 细胞疗法 - 毒性的评估和管理。
Nat Rev Clin Oncol. 2018 Jan;15(1):47-62. doi: 10.1038/nrclinonc.2017.148. Epub 2017 Sep 19.
5
How to Treat Involvement of the Central Nervous System in Hemophagocytic Lymphohistiocytosis?如何治疗噬血细胞性淋巴组织细胞增生症的中枢神经系统受累？
Curr Treat Options Neurol. 2017 Jan;19(1):3. doi: 10.1007/s11940-017-0439-4.
6
Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia.嵌合抗原受体T细胞疗法治疗急性淋巴细胞白血病后的细胞因子释放综合征
Crit Care Med. 2017 Feb;45(2):e124-e131. doi: 10.1097/CCM.0000000000002053.
7
Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells.使用睡美人转座子系统生成CD19特异性嵌合抗原受体T细胞的I期试验。
J Clin Invest. 2016 Sep 1;126(9):3363-76. doi: 10.1172/JCI86721. Epub 2016 Aug 2.
8
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia.嵌合抗原受体T细胞在复发难治性慢性淋巴细胞白血病中持续存在并诱导持续缓解。
Sci Transl Med. 2015 Sep 2;7(303):303ra139. doi: 10.1126/scitranslmed.aac5415.
9
Multicenter study of combination DEP regimen as a salvage therapy for adult refractory hemophagocytic lymphohistiocytosis.多中心研究联合DEP方案作为成人难治性噬血细胞性淋巴组织细胞增生症的挽救治疗方法
Blood. 2015 Nov 5;126(19):2186-92. doi: 10.1182/blood-2015-05-644914. Epub 2015 Aug 19.
10
Current concepts in the diagnosis and management of cytokine release syndrome.细胞因子释放综合征的诊断和治疗的当前概念。
Blood. 2014 Jul 10;124(2):188-95. doi: 10.1182/blood-2014-05-552729. Epub 2014 May 29.
Zotero 插件